A sector once defined by a single dominant platform is now one of the fastest-expanding categories in medical technology. According to Precedence Research, the global minimally invasive medical robots market was valued at approximately $58.2 billion in 2025 and is projected to grow to around $183 billion by 2034, expanding at a compound annual growth rate of roughly 13.6%. North America remains the anchor of that growth, accounting for the largest regional share at 43%, a position the firm attributes to the presence of leading market players, widespread adoption of robotic technologies, and well-established healthcare systems capable of supporting complex surgical procedures.
The surgical robotics field, more specifically, is on a comparable trajectory. The surgical robots market was valued at $11.33 billion in 2025 and is projected to reach $38.27 billion by 2035, expanding at a compound annual growth rate of nearly 13% over that period. The underlying driver is straightforward: patients want shorter recovery times, lower infection risk, and fewer complications. Hospitals want fewer readmissions, better outcomes, and procedures that fit an increasingly outpatient-oriented care model. Robotic surgery addresses all of those priorities at once. [SNS Insider, 2026]
Intuitive Surgical, Inc. (NASDAQ: ISRG), Medtronic plc (NYSE: MDT), Stryker Corporation (NYSE: SYK), Johnson & Johnson (NYSE: JNJ), Globus Medical, Inc. (NYSE: GMED), and Zimmer Biomet Holdings, Inc. (NYSE: ZBH) are among the key players operating across soft tissue and orthopedic robotic segments. CMR Surgical’s Versius platform has expanded across more than 20 markets in Europe, India, and Latin America, offering a modular, portable alternative suited to hospitals with smaller operating rooms. Shanghai MicroPort MedBot (Group) Co., Ltd. (HKEX: 2252) is broadening international reach with a diverse robotic portfolio spanning laparoscopic, orthopedic, and vascular procedures.
Intuitive Surgical continues to hold a commanding lead, supported by an installed base exceeding 11,100 da Vinci systems and more than 3.1 million procedures completed in 2025. Its fifth-generation system integrates force feedback, AI-enabled workflow optimization, and enhanced imaging, pushing the platform further into cardiac applications. Medtronic highlighted FDA clearance for its Hugo robotic system in urologic procedures and early installations in U.S. hospitals, though management has framed the launch as purposeful and gradual, underscoring that the platform is still building market credibility.
Two broader trends are reshaping how the industry competes. First, artificial intelligence. AI-assisted robotic surgeries have demonstrated meaningful reductions in operative time and intraoperative complications compared to conventional manual methods. Second, the shift toward modularity. The industry is moving away from large fixed-tower installations toward cart-based platforms that can be repositioned across procedure suites, lowering the adoption barrier for mid-sized hospitals and ambulatory surgical centers. Of roughly 50 million soft tissue surgeries performed globally each year, approximately 30 million are still performed as open surgery, representing a substantial runway for robotic expansion. Reimbursement frameworks are beginning to catch up as well. The American Medical Association issued a new CPT code for robotic lymphovenous bypass surgery, effective January 2026, signaling that payer structures are gradually aligning with the technology.
Against that backdrop, a smaller player just picked up an honor typically associated with much larger platforms. Microbot Medical Inc. (NASDAQ: MBOT) has been named the recipient of the Innovative Start-Up Award at the 2026 Surgical Robotics Industry Awards, presented by Surgical Robotics Technology. The award recognizes companies with outstanding technological and commercial progress through highly innovative, groundbreaking technologies with the potential for broad healthcare impact. The company received the recognition for its LIBERTY Endovascular Robotic System, the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed for precise vascular navigation while aiming to enhance efficiency and reduce radiation exposure and physical strain on clinicians.
Harel Gadot, CEO, President and Chairman of Microbot Medical, noted that the award is more than a milestone, calling it a powerful affirmation of the company’s mission to redefine endovascular robotics by establishing a new category of surgical robotics and expanding what is possible for clinicians and their patients. The single-use design is not a minor detail. It addresses hospital infection control priorities directly and eliminates the cost and complexity of sterilization. More importantly, FDA clearance in this specific application means that any hospital choosing a peripheral endovascular robotic system is currently choosing from a market of one. In a sector where clinical recognition at major industry events can open doors to hospital purchasing conversations and institutional partnership inquiries, that is a meaningful combination of regulatory validation and commercial momentum arriving at the same time.
